Orange is one of the world’s leading telecommunications operators with sales of EUR 41 billion in 2018 and 151,000 employees worldwide at 31 December 2018, including 92,000 employees in France. The Group has a total customer base of 264 million customers worldwide at 31 December 2018, including 204 million mobile customers and 20 million fixed broadband customers. The Group is present in 27 countries. Orange is also a leading provider of global IT and telecommunication services to multinational companies, under the brand Orange Business Services.
In addition to reshaping societies, digital technology is opening up new growth opportunities for Orange. The overarching aim of the company is to build a more intelligent, more open and more responsible society. That involves rising to the challenges that the digital revolution is bringing about, i.e. harnessing innovation to make it useful and make sure its benefits reach as many people as possible.
Gavi and Orange Middle East and Africa recognise the importance of mobile health solutions to improve the efficiency of national health systems, especially in reaching the millions of children who continue to miss out on life-saving vaccines that protect them for life.
Gavi and Orange SA signed a letter of intent in 2017 to explore ways to collaborate to assist Gavi-supported countries to reinforce the interface between local communities and health facilities, leading to improvement in the quality of health services and as a consequence, to increase immunization coverage, reduce vaccine wastage, increase efficiency and better ensure vaccine potency.
In Côte d'Ivoire, insufficient data is one of the biggest obstacles to immunising children and parents do not always know when to bring their child for vaccination. To address this problem, Gavi, the Ministry of Health of Cote d’Ivoire and Orange Cote d’Ivoire, the country's leading telecommunications provider signed a tripartite partnership agreement in 2018 to design and use m-Vaccin Côte d'Ivoire, a mobile phone application to improve EPI data and demand generation with the aim of increasing immunisation coverage. M-Vaccin uses text and voice messages to provide vaccination information and remind parents of appointments in local languages. The application also helps health workers collect data to create personalised electronic immunisation schedules for each family, with the aim of reducing dropouts.
As of June 2021, the roll-out of the solution in the first 3 districts where the solution was most needed was effective with successful supervision and monitoring of activities during the period of travel restrictions due to COVID 19. Over 200 health workers have been trained and equipped with mobile phones with the application, over 12,200 mothers enrolled, and a population of more than 27,500 inhabitants covered. The solution will be extended to 7 more health districts before being transferred to the Ivorian government.
Since 2019, Orange has been working with USAID, Resolve and GAVI to develop a methodology for use within Orange’s own business expansion plans in West Africa that will provide off-grid health facilities with photovoltaic-based electricity systems paired with Orange Internet connectivity systems. The methodology also provides an opportunity to layer-on additional public health services and products that likewise require reliable electricity and connectivity such as cold-chain for vaccine distribution, which is the key concern of the Sierra Leonean government and its Expanded Program on Immunization (“EPI”). A pilot project will be launched in 2021 to test this model in Sierra Leone through a multi-stakeholder partnership between Gavi, Orange, USAID Guinea and Sierra Leone and the Sierra Leone Ministry of Health.
This MicroUtilities for Community Health partnership project will provide thirty-one rural health facilities in Sierra Leone with off-grid renewable electricity generation and storage systems as well as Internet connectivity systems. The partners will also test a model for using the access to electricity that the project will enable to produce purified drinking water for 8 health facilities. This programme will only be carried out in health facilities that are not covered by the country current CCEOP plan and that have not been equipped with solar refrigerators.
For more information about Orange, please visit https://healthcare.orange.com/en/
Proceeds are funds made available to Gavi from donor contributions and commitments, either through cash payments made to Gavi, through frontloading via the capital markets of a future donor commitment to IFFIm, or through AMC funds released to Gavi via the World Bank. IFFIm proceeds are allocated over five-year periods coinciding with Gavi’s strategic periods. Proceeds for the current and future strategic periods are indicative until the end of each period and could be revised following changes in market conditions (interest rates or foreign exchange rates), the signing of new pledge(s) and/or changes in IFFIm’s disbursement profile.
Click on Direct, IFFIm, AMC or Matching Fund in the above key to toggle their data on the graph, click again to show the data
Direct Contributions (including Matching Fund)
Received contributions: non-US$ contributions for 2000-2020 and Q1-Q2 2021 are expressed in US$ equivalents using the exchange rates on the dates of receipt. For 2014-2020 and Q1-Q2 2021 where contributions were hedged to mitigate currency risk exposure, these have been expressed using the rates applicable to the hedge agreement.
Future contributions (for pledges made prior to the June 2020 donor pledging conference): non-US$ Direct Contribution and Matching Fund pledges for Q3-Q4 2021 and years 2022 and beyond are expressed in US$ equivalents using the applicable forecast rates from Bloomberg as at 30 June 2021 or using the rates applicable to any hedge agreement in place.
Future contributions (for pledges at the June 2020 donor pledging conference): non-US$ Direct Contribution and Matching Fund pledges for Q3-Q4 2021 and for years 2022 and beyond are expressed in US$ equivalents using the spot rates from Bloomberg as at 30 June 2021 or using the rates applicable to any hedge agreement in place.
Received contributions: non-US$ contributions for 2000-2020 and for Q1-Q2 2021 are expressed in US$ equivalents as confirmed by the IBRD (World Bank)
'Future contributions: non-US$ contributions for Q3-Q4 2021 and for years 2021 and beyond are expressed in US$ equivalents as follows:
For signed contribution agreements: contributions are expressed in US$ equivalents using the exchange rates at the time of signing the respective donor grant agreements.
For contribution agreements not yet signed: contributions are expressed in US$ equivalents using the applicable spot rates from Bloomberg as at 30 June 2021
Due to IFFIm’s nature as a frontloading vehicle, yearly contributions paid into IFFIm can differ significantly from yearly proceeds transferred to Gavi.
'While IFFIm grants are irrevocable and legally binding, they are subject to a Grant Payment Condition that can potentially reduce the amount due by the donor in the event that a Gavi-supported programme country is in protracted arrears with the International Monetary Fund. As of 29 June 2021, there is no longer any reduction applied, as all countries from the reference portfolio have cleared their arrears with the IMF.